Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Noven Pharmaceuticals has appointed Steven Dinh as its new vice president and chief scientific officer. In this role, Mr Dinh will be responsible for the functioning, expansion and productivity of Noven's transdermal drug delivery program and related transdermal product development activities.
Subscribe to our email newsletter
Mr Dinh has more than 25 years experience in drug delivery, biotechnology, pharmaceutical development and polymer engineering.
Mr Dinh joins Noven from Emisphere Technologies, last serving in the dual role of vice president of research and technology development and co-chair – office of the president. Earlier, Mr Dinh served as chief scientific officer and vice president of R&D for Lavipharm Laboratories. Before that, Mr Dinh held several senior-level R&D positions focused in transdermal and pharmaceutical R&D for Novartis Pharmaceuticals and Ciba-Geigy.
Peter Brandt, president and CEO of Noven, said: “He will play a key role in our efforts to establish seamless collaboration among R&D, quality and operations to assure that what emerges from our transdermal pipeline is scalable and ready for the commercial market.”